PT2139494T - Formulações farmacêuticas que contêm hidrato de propilenoglicol de dapagliflozina - Google Patents

Formulações farmacêuticas que contêm hidrato de propilenoglicol de dapagliflozina

Info

Publication number: PT2139494T
Authority: PT; Portugal
Prior art keywords: propylene glycol; pharmaceutical formulations; formulations containing; glycol hydrate; dapagliflozin propylene
Prior art date: 2007-03-22

Application number

PT87326955T

Other languages

English (en)

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-22

Filing date

2008-03-21

Publication date

2020-05-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39671801&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2139494(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-03-21 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2020-05-19 Publication of PT2139494T publication Critical patent/PT2139494T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Child & Adolescent Psychology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PT87326955T 2007-03-22 2008-03-21 Formulações farmacêuticas que contêm hidrato de propilenoglicol de dapagliflozina PT2139494T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US89628607P	2007-03-22	2007-03-22

Publications (1)

Publication Number	Publication Date
PT2139494T true PT2139494T (pt)	2020-05-19

Family

ID=39671801

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT87326955T PT2139494T (pt)	2007-03-22	2008-03-21	Formulações farmacêuticas que contêm hidrato de propilenoglicol de dapagliflozina
PT121539399T PT2508188T (pt)	2007-03-22	2008-03-21	Formulações farmacêuticas que contêm hidrato de propilenoglicol de dapagliflozina

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT121539399T PT2508188T (pt)	2007-03-22	2008-03-21	Formulações farmacêuticas que contêm hidrato de propilenoglicol de dapagliflozina

Country Status (29)

Country	Link
US (5)	US7851502B2 (pt)
EP (3)	EP2139494B1 (pt)
JP (2)	JP5475636B2 (pt)
KR (5)	KR101454051B1 (pt)
CN (2)	CN102743340B (pt)
AR (1)	AR065809A1 (pt)
AU (1)	AU2008228714B2 (pt)
BR (2)	BRPI0809233B1 (pt)
CA (2)	CA2929811C (pt)
CL (1)	CL2008000823A1 (pt)
CY (3)	CY1123143T1 (pt)
DK (2)	DK2139494T3 (pt)
EA (2)	EA020288B1 (pt)
ES (2)	ES2950089T3 (pt)
FI (1)	FI2508188T3 (pt)
FR (1)	FR20C1042I1 (pt)
HK (1)	HK1176004A1 (pt)
HR (2)	HRP20230691T1 (pt)
HU (3)	HUE062284T2 (pt)
LT (3)	LT2139494T (pt)
MX (4)	MX374797B (pt)
NO (1)	NO2020028I1 (pt)
PE (1)	PE20090185A1 (pt)
PL (2)	PL2508188T3 (pt)
PT (2)	PT2139494T (pt)
RS (1)	RS60258B1 (pt)
SI (2)	SI2139494T1 (pt)
TW (1)	TW200904405A (pt)
WO (1)	WO2008116179A1 (pt)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA91546C2 (uk) *	2005-05-03	2010-08-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) *	2005-05-10	2010-08-10	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
TW200726755A (en) *	2005-07-07	2007-07-16	Astellas Pharma Inc	A crystalline choline salt of an azulene derivative
PE20080697A1 (es) *	2006-05-03	2008-08-05	Boehringer Ingelheim Int	Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
EP2105442A4 (en)	2006-12-21	2013-01-23	Astellas Pharma Inc	PROCESS FOR PREPARING A C-GLYCOSIDE DERIVATIVE AND SYNTHETIC INTERMEDIATE PRODUCT THEREFOR
TW200904454A (en) *	2007-03-22	2009-02-01	Bristol Myers Squibb Co	Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
PE20090185A1 (es) *	2007-03-22	2009-02-28	Bristol Myers Squibb Co	Formulaciones farmaceuticas que contienen un inhibidor sglt2
CL2008002427A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
NO2200606T3 (pt) *	2007-09-10	2018-03-24
JP5302900B2 (ja) *	2008-01-31	2013-10-02	アステラス製薬株式会社	脂肪性肝疾患の治療用医薬組成物
ES2526930T3 (es) *	2008-05-22	2015-01-16	Astrazeneca Ab	Método para el tratamiento de la hiperuricemia empleando un inhibidor de SGLT2 y composición que contiene el mismo
EP2312944B1 (en)	2008-07-15	2018-09-05	Theracos, Inc.	Deuterated benzylbenzene derivatives and methods of use
WO2010045656A2 (en) *	2008-10-17	2010-04-22	Nectid, Inc.	Novel sglt2 inhibitor dosage forms
US9056850B2 (en) *	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
CA2751834C (en)	2009-02-13	2018-07-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
EA024072B1 (ru) *	2009-02-13	2016-08-31	Бёрингер Ингельхайм Интернациональ Гмбх	Фармацевтическая дозированная форма, включающая производное глюкопиранозилдифенилметана, и применения для улучшения гликемического контроля у пациентов
JP2012528170A (ja) *	2009-05-27	2012-11-12	ブリストル−マイヤーズスクイブカンパニー	別の抗糖尿病薬を用いた先の治療に抵抗性を有する２型糖尿病患者をｓｇｌｔ２阻害剤およびその組成物を用いて治療する方法
US20110009347A1 (en) *	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
CA2767258C (en)	2009-07-10	2016-09-13	Janssen Pharmaceutica Nv	Crystallisation process for 1-(.beta.-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene
PH12012500633B1 (en)	2009-09-30	2017-12-13	Boehringer Ingelheim Int	Method for the preparation of a crystalline form of 1-chloro -4- (beta -d- glucopyranos -1-yl) -2- (4-((s)- tetrahydrofuran -3- yloxy) benzyl) benzene
DK2486029T3 (en)	2009-09-30	2015-08-24	Boehringer Ingelheim Int	Methods of making of glucopyranosyl-substituted benzyl-benzene derivatives.
UY32919A (es) *	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
BR112012008939B1 (pt) *	2009-10-14	2021-06-22	Janssen Pharmaceutica Nv	Processo para a preparação de compostos úteis como inibidores de sglt2
AU2014218385B2 (en) *	2009-11-13	2016-02-25	Astrazeneca Ab	Bilayer tablet formulations
AU2010319377B2 (en)	2009-11-13	2014-10-23	Astrazeneca Ab	Immediate release tablet formulations
EP2498758B1 (en) *	2009-11-13	2018-07-25	AstraZeneca AB	Bilayer tablet formulations
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2368552A1 (en) *	2010-03-25	2011-09-28	Boehringer Ingelheim Vetmedica GmbH	1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
JP2013523681A (ja) *	2010-03-30	2013-06-17	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
EP2568971B1 (en) *	2010-05-11	2020-10-14	Mitsubishi Tanabe Pharma Corporation	Canagliflozin containing tablets
MX339570B (es)	2010-05-11	2016-05-31	Janssen Pharmaceutica Nv	Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio.
WO2011157827A1 (de)	2010-06-18	2011-12-22	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US20120009259A1 (en) *	2010-07-06	2012-01-12	Urbain Alfons Clementina Delaet	Formulation for co-therapy treatment of diabetes
WO2012005340A1 (ja) *	2010-07-07	2012-01-12	日本たばこ産業株式会社	クエン酸第二鉄を含む錠剤
US20130224296A1 (en)	2010-09-03	2013-08-29	Bristol-Myers Squibb Company	Drug Formulations Using Water Soluble Antioxidants
US20120283169A1 (en)	2010-11-08	2012-11-08	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
TWI631963B (zh) *	2011-01-05	2018-08-11	雷西肯製藥股份有限公司	包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
RU2607480C2 (ru) *	2011-02-01	2017-01-10	Бристол-Майерс Сквибб Компани	Фармацевтические композиции, содержащие аминосоединение
US20130035281A1 (en)	2011-02-09	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
UY33937A (es)	2011-03-07	2012-09-28	Boehringer Ingelheim Int	Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
DK2697218T3 (en)	2011-04-13	2016-07-25	Janssen Pharmaceutica Nv	PROCESS FOR THE PREPARATION OF COMPOUNDS useful as inhibitors of SGLT2
US9035044B2 (en)	2011-05-09	2015-05-19	Janssen Pharmaceutica Nv	L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
EP2529742B1 (en)	2011-06-03	2013-11-20	ratiopharm GmbH	Pharmaceutical composition comprising dapagliflozin and cyclodextrin
EP2714049A1 (en)	2011-06-03	2014-04-09	Ratiopharm GmbH	Pharmaceutical composition comprising dapagliflozin and cyclodextrin
WO2012163990A1 (en)	2011-06-03	2012-12-06	Boehringer Ingelheim International Gmbh	Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2851862C (en) *	2011-10-17	2020-04-14	Lexicon Pharmaceutical Inc.	Solid dosage forms of (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
EP2597090A1 (en)	2011-11-28	2013-05-29	Sandoz AG	Crystalline dapagliflozin hydrate
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US9192617B2 (en)	2012-03-20	2015-11-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US9145434B2 (en)	2012-07-26	2015-09-29	Boehringer Ingelheim International Gmbh	Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
BR112015004012A2 (pt) *	2012-08-30	2017-07-04	Taisho Pharmaceutical Co Ltd	combinações de inibidores de sglt 2 e fármacos anti-hipertensivos
CN113842362A (zh)	2012-11-14	2021-12-28	格雷斯公司	含有生物活性材料与无序无机氧化物的组合物
PT3466431T (pt)	2013-03-14	2024-01-26	Msd Int Gmbh	Formas cristalinas e métodos para preparação de inibidores de sglt2
ES2959444T3 (es)	2013-04-04	2024-02-26	Boehringer Ingelheim Vetmedica Gmbh	Tratamiento de trastornos metabólicos en animales equinos
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
ES2702174T3 (es)	2013-04-05	2019-02-27	Boehringer Ingelheim Int	Usos terapéuticos de empagliflozina
US20140303097A1 (en)	2013-04-05	2014-10-09	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
MX381599B (es)	2013-04-18	2025-03-12	Boehringer Ingelheim Int Gmbh	Empagliflozina para usarse en el tratamiento de micro y macroalbuminuria
EP2991999B1 (en)	2013-04-29	2019-05-08	Mapi Pharma Limited	Dapagliflozin lactose co-crystal
KR20160034348A (ko) *	2013-07-22	2016-03-29	산도즈 아게	무정형 다파글리플로진을 함유하는 제제
WO2015091313A1 (en) *	2013-12-17	2015-06-25	Boehringer Ingelheim Vetmedica Gmbh	Treatment of metabolic disorders in feline animals
EP3482748A1 (en) *	2013-12-27	2019-05-15	Chugai Seiyaku Kabushiki Kaisha	Solid preparations containing tofogliflozin and method for producing the same
WO2015104658A2 (en) *	2014-01-08	2015-07-16	Dr. Reddy’S Laboratories Limited	Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
WO2015110402A1 (en) *	2014-01-23	2015-07-30	Boehringer Ingelheim Vetmedica Gmbh	Treatment of metabolic disorders in canine animals
US20170056365A1 (en)	2014-02-28	2017-03-02	Sun Pharmaceutical Industries Limited	Dapagliflozin compositions
AU2015239655B2 (en)	2014-04-01	2019-10-24	Boehringer Ingelheim Vetmedica Gmbh	Treatment of metabolic disorders in equine animals
KR20160013770A (ko) *	2014-07-28	2016-02-05	한미정밀화학주식회사	다파글리프로진의 신규 결정질 복합체 및 이의 제조방법
ES2991763T3 (es)	2014-09-25	2024-12-04	Boehringer Ingelheim Vetmedica Gmbh	Tratamiento de combinación de inhibidores de SGLT2 y agonistas de dopamina para la prevención de trastornos metabólicos en animales equinos
WO2016055945A1 (en) *	2014-10-08	2016-04-14	Dr. Reddy’S Laboratories Limited	Polymorphs of canagliflozin
CN104496952B (zh) *	2014-11-28	2017-04-19	深圳翰宇药业股份有限公司	一种达格列净的合成方法
FI3341024T3 (fi)	2015-08-27	2024-12-18	Boehringer Ingelheim Vetmedica Gmbh	Sglt-2-estäjiä käsittäviä nestemäisiä farmaseuttisia koostumuksia
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN105853386B (zh) *	2016-04-01	2020-01-07	北京凯莱天成医药科技有限公司	一种含有达格列净丙二醇水合物的片剂及其制造方法
WO2017203229A1 (en) *	2016-05-27	2017-11-30	Cipla Limited	Dapagliflozin premixes
US11007172B2 (en) *	2016-08-30	2021-05-18	Niigata University	Agent for eliminating senescent cells
MX2019004549A (es)	2016-10-19	2019-06-12	Boehringer Ingelheim Int	Combinaciones que comprenden un inhibidor ssao/vap-1 y un inhibidor sglt2 y usos de los mismos.
US11020412B2 (en)	2017-03-16	2021-06-01	Inventia Healthcare Limited	Pharmaceutical composition comprising dapagliflozin
WO2018200534A1 (en) *	2017-04-24	2018-11-01	Samus Therapeutics, Inc.	Hsp90 inhibitor oral formulations and related methods
US20230190714A1 (en) *	2017-05-11	2023-06-22	Richard Postrel	Primary methods and processes for life extension in modern-day humans
AR112015A1 (es)	2017-06-09	2019-09-11	Novo Nordisk As	Composiciones sólidas para administración oral
KR102025480B1 (ko)	2017-12-12	2019-09-25	영남대학교 산학협력단	다파글리플로진 유리염기를 함유하는 약제학적 조성물 및 이의 제조방법
WO2019162841A1 (en) *	2018-02-21	2019-08-29	Glenmark Pharmaceuticals Limited	Pharmaceutical composition comprising remogliflozin for treatment of diabetes mellitus
AU2019254371A1 (en)	2018-04-17	2020-10-08	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
WO2019241568A1 (en)	2018-06-14	2019-12-19	Astrazeneca Uk Limited	Methods for lowering blood sugar with a gliflozin sodium-glucose cotransporter 2 inhibitor pharmaceutical composition
WO2020039394A1 (en)	2018-08-24	2020-02-27	Novartis Ag	New drug combinations
US11346786B2 (en) *	2018-10-09	2022-05-31	Sensor International, Llc	High pressure sensitive color changeable indicators and methods of making such indicators
JP7425793B2 (ja)	2018-10-29	2024-01-31	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用
CA3112510A1 (en)	2018-10-29	2020-05-07	Boehringer Ingelheim International Gmbh	Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
US11033544B2 (en) *	2019-03-25	2021-06-15	The George Institute for Global Health	Low-dose triple combination formulation
KR102234154B1 (ko)	2019-06-18	2021-03-31	삼천당제약주식회사	다파글리플로진비용매화물 함유 정제 제조방법 및 그에 의해 제조된 다파글리플로진비용매화물 함유 정제
JOP20200098A1 (ar) *	2019-08-30	2021-02-28	Astrazeneca Ab	طرق علاج الفشل القلبي مع كسر قذفي منخفض بواسطة داباجليفلوزين
UY38969A (es)	2019-11-28	2021-05-31	Boehringer Ingelheim Vetmedica Gmbh	Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos
BR112022016360A2 (pt)	2020-02-17	2022-10-04	Boehringer Ingelheim Vetmedica Gmbh	Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos
WO2021165316A1 (en)	2020-02-21	2021-08-26	Zakłady Farmaceutyczne POLPHARMA S.A.	Pharmaceutical composition comprising dapagliflozin
WO2021176096A1 (en)	2020-03-05	2021-09-10	Krka, D.D., Novo Mesto	Pharmaceutical composition comprising sglt2 inhibitor
CA3180674A1 (en)	2020-04-22	2021-10-28	Bayer Aktiengesellschaft	Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
EP4161912A1 (en)	2020-06-05	2023-04-12	KRKA, d.d., Novo mesto	Preparation of highly pure amorphous dapagliflozin
TR202019592A2 (tr)	2020-12-03	2022-06-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Amorf dapagliflozinin katı farmasötik formülasyonları
AU2022251165A1 (en)	2021-04-01	2023-11-09	Astrazeneca Uk Limited	Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
MX2024001184A (es)	2021-07-28	2024-02-27	Boehringer Ingelheim Vetmedica Gmbh	Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
CA3224673A1 (en)	2021-07-28	2023-02-02	Boehringer Ingelheim Vetmedica Gmbh	Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
US20240269105A1 (en)	2021-07-28	2024-08-15	Boehringer Ingelheim Vetmedica Gmbh	Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
CN113648304A (zh) *	2021-09-06	2021-11-16	扬子江药业集团上海海尼药业有限公司	一种含达格列净的药物组合物及其制备方法和应用
KR20230084974A (ko)	2021-12-06	2023-06-13	에이치케이이노엔 주식회사	다파글리플로진 프로판디올 수화물을 포함하는 습식 과립 조성물, 과립물, 정제, 이들의 제조 방법, 및 상기 제조 방법으로 제조된 과립물 또는 정제
IL314031A (en)	2021-12-30	2024-09-01	Newamsterdam Pharma B V	Materials and methods for improved phosphotransferases
CN118510504A (zh) *	2022-01-26	2024-08-16	阿斯利康(瑞典)有限公司	用于在治疗糖尿病前期或降低发展2型糖尿病的风险中使用的达格列净
US20230381101A1 (en)	2022-05-25	2023-11-30	Boehringer Ingelheim Vetmedica Gmbh	Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
KR102490653B1 (ko)	2022-08-03	2023-01-20	진양제약주식회사	다파글리플로진 및 글리메피리드를 포함하는 약제학적 조성물
US20240307628A1 (en)	2023-03-06	2024-09-19	Boehringer Ingelheim Vetmedica Gmbh	Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
WO2024226537A1 (en)	2023-04-24	2024-10-31	Newamsterdam Pharma B.V.	Amorphous obicetrapib and sglt2 inhibitor combination
US20240390317A1 (en)	2023-05-24	2024-11-28	Boehringer Ingelheim Vetmedica Gmbh	Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
US20240390332A1 (en)	2023-05-24	2024-11-28	Boehringer Ingelheim Vetmedica Gmbh	Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3674836A (en)	1968-05-21	1972-07-04	Parke Davis & Co	2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en)	1973-06-11	1977-05-31	Merck & Co., Inc.	Compositions and methods for depressing blood serum cholesterol
US3970651A (en)	1974-01-07	1976-07-20	Bristol-Myers Company	Crystalline cephalosporin derivative
JPS5612114B2 (pt)	1974-06-07	1981-03-18
JPS5495589A (en)	1977-12-30	1979-07-28	Sumitomo Chem Co Ltd	Production of cephalosporin derivative
US4231938A (en)	1979-06-15	1980-11-04	Merck & Co., Inc.	Hypocholesteremic fermentation products and process of preparation
DK149080C (da)	1980-06-06	1986-07-28	Sankyo Co	Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en)	1980-08-05	1984-05-22	Merck & Co., Inc.	Antihypercholesterolemic compounds
US4448784A (en)	1982-04-12	1984-05-15	Hoechst-Roussel Pharmaceuticals, Inc.	1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en)	1982-11-22	1994-10-11	Sandoz Pharm. Corp.	Indole analogs of mevalonolactone and derivatives thereof
US4499289A (en)	1982-12-03	1985-02-12	G. D. Searle & Co.	Octahydronapthalenes
CA1327360C (en)	1983-11-14	1994-03-01	William F. Hoffman	Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en)	1984-06-22	1986-09-23	Sandoz Pharmaceuticals Corp.	Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en)	1984-07-24	1987-08-11	Sandoz Pharmaceuticals Corp.	Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en)	1984-09-24	1987-03-03	Warner-Lambert Company	Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
ATE60571T1 (de)	1984-12-04	1991-02-15	Sandoz Ag	Inden-analoga von mevalonolakton und ihre derivate.
US4668794A (en)	1985-05-22	1987-05-26	Sandoz Pharm. Corp.	Intermediate imidazole acrolein analogs
AU598775B2 (en)	1985-10-25	1990-07-05	Sandoz Ag	Heterocyclic analogs of mevalonolactone
FR2596393B1 (fr)	1986-04-01	1988-06-03	Sanofi Sa	Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US5614492A (en)	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4681893A (en)	1986-05-30	1987-07-21	Warner-Lambert Company	Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
ES2009918A6 (es)	1987-05-22	1989-10-16	Squibb & Sons Inc	Procedimiento para preparar inhibidores de hmg-coa-reductasa que contienen fosforo.
US4759923A (en)	1987-06-25	1988-07-26	Hercules Incorporated	Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
JP2569746B2 (ja)	1987-08-20	1997-01-08	日産化学工業株式会社	キノリン系メバロノラクトン類
US4871721A (en)	1988-01-11	1989-10-03	E. R. Squibb & Sons, Inc.	Phosphorus-containing squalene synthetase inhibitors
US4924024A (en)	1988-01-11	1990-05-08	E. R. Squibb & Sons, Inc.	Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
NO177005C (no)	1988-01-20	1995-07-05	Bayer Ag	Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5506219A (en)	1988-08-29	1996-04-09	E. R. Squibb & Sons, Inc.	Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en)	1989-03-03	1998-05-19	Novartis Pharmaceuticals Corporation	Quinoline analogs of mevalonolactone and derivatives thereof
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en)	1990-12-14	1993-01-05	Bayer Aktiengesellschaft	Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja)	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
US5595872A (en)	1992-03-06	1997-01-21	Bristol-Myers Squibb Company	Nucleic acids encoding microsomal trigyceride transfer protein
US5712396A (en)	1992-10-28	1998-01-27	Magnin; David R.	α-phosphonosulfonate squalene synthetase inhibitors
US5594016A (en)	1992-12-28	1997-01-14	Mitsubishi Chemical Corporation	Naphthalene derivatives
ES2133158T3 (es)	1993-01-19	1999-09-01	Warner Lambert Co	Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
US5340583A (en)	1993-05-06	1994-08-23	Allergan, Inc.	Antimicrobial lenses and lens care systems
US5739135A (en)	1993-09-03	1998-04-14	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
US5776983A (en)	1993-12-21	1998-07-07	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
US5488064A (en)	1994-05-02	1996-01-30	Bristol-Myers Squibb Company	Benzo 1,3 dioxole derivatives
US5385929A (en)	1994-05-04	1995-01-31	Warner-Lambert Company	[(Hydroxyphenylamino) carbonyl] pyrroles
US5612359A (en)	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
US5491134A (en)	1994-09-16	1996-02-13	Bristol-Myers Squibb Company	Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en)	1994-12-02	1996-07-30	Bristol-Myers Squibb Company	Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en)	1995-05-31	1997-04-15	Warner-Lambert Company	Isothiazolones
WO1997012613A1 (en)	1995-10-05	1997-04-10	Warner-Lambert Company	Method for treating and preventing inflammation and atherosclerosis
EP0873361B1 (en)	1995-12-13	2006-11-02	The Regents Of The University Of California	Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand
US5770615A (en)	1996-04-04	1998-06-23	Bristol-Myers Squibb Company	Catecholamine surrogates useful as β3 agonists
US5962440A (en)	1996-05-09	1999-10-05	Bristol-Myers Squibb Company	Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en)	1996-05-10	1998-10-27	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en)	1996-05-10	1999-03-23	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
US6077539A (en) *	1996-11-12	2000-06-20	Pozen, Inc.	Treatment of migraine headache
US5760246A (en)	1996-12-17	1998-06-02	Biller; Scott A.	Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
TW536540B (en)	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9713739D0 (en)	1997-06-27	1997-09-03	Karobio Ab	Thyroid receptor ligands
WO1999038501A2 (en)	1998-02-02	1999-08-05	Trustees Of Tufts College	Method of regulating glucose metabolism, and reagents related thereto
EP1062222A1 (en)	1998-03-09	2000-12-27	Fondatech Benelux N.V.	Serine peptidase modulators
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
ID26984A (id)	1998-07-06	2001-02-22	Bristol Myers Squibb Co	Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
US6342249B1 (en) *	1998-12-23	2002-01-29	Alza Corporation	Controlled release liquid active agent formulation dosage forms
GB9828442D0 (en)	1998-12-24	1999-02-17	Karobio Ab	Novel thyroid receptor ligands and method II
US6548529B1 (en)	1999-04-05	2003-04-15	Bristol-Myers Squibb Company	Heterocyclic containing biphenyl aP2 inhibitors and method
US6414002B1 (en)	1999-09-22	2002-07-02	Bristol-Myers Squibb Company	Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TWI302149B (en)	1999-09-22	2008-10-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
PH12000002657B1 (en) *	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en)	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
EE05442B1 (et) *	2000-02-29	2011-08-15	Bristol-Myers Squibb Company	Vikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
ATE318272T1 (de)	2001-04-11	2006-03-15	Bristol Myers Squibb Co	Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
KR100431431B1 (ko)	2001-04-25	2004-05-14	한미약품 주식회사	아지트로마이신 수화물의 1,2-프로필렌글리콜 내포화합물,그의 제조방법 및 그의 약학적 조성물
CN1630709A (zh)	2001-10-18	2005-06-22	百时美施贵宝公司	人胰高血糖素样多肽－1模拟物和它们在治疗糖尿病和相关状况中的应用
WO2004060347A2 (en)	2002-09-03	2004-07-22	Transform Pharmaceuticals, Inc.	Pharmaceutical propylene glycol solvate compositions
WO2004061433A1 (en) *	2002-12-30	2004-07-22	Transform Pharmaceuticals, Inc.	Pharmaceutical compositions with improved dissolution
US7790905B2 (en)	2002-02-15	2010-09-07	Mcneil-Ppc, Inc.	Pharmaceutical propylene glycol solvate compositions
WO2003101392A2 (en) *	2002-05-31	2003-12-11	Transform Pharmaceuticals, Inc.	Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
CA2512389A1 (en) *	2003-01-03	2004-07-29	Bristol-Myers Squibb Company	Methods of producing c-aryl glucoside sglt2 inhibitors
US7164015B2 (en)	2003-02-27	2007-01-16	Bristol-Myers Squibb Company	Non-cryogenic process for forming glycosides
TWI415635B (zh)	2004-05-28	2013-11-21	必治妥施貴寶公司	加衣錠片調製物及製備彼之方法
AR051446A1 (es)	2004-09-23	2007-01-17	Bristol Myers Squibb Co	Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
JP5086643B2 (ja)	2004-11-18	2012-11-28	キッセイ薬品工業株式会社	１−置換−３−（β−Ｄ−グリコピラノシル）含窒素ヘテロ環化合物、及びそれを含有する医薬
US7919598B2 (en) *	2006-06-28	2011-04-05	Bristol-Myers Squibb Company	Crystal structures of SGLT2 inhibitors and processes for preparing same
PE20090185A1 (es)	2007-03-22	2009-02-28	Bristol Myers Squibb Co	Formulaciones farmaceuticas que contienen un inhibidor sglt2
KR101483259B1 (ko)	2012-08-28	2015-01-14	주식회사 아모센스	무수축 바리스타 기판 및 그 제조 방법
EP2991999B1 (en)	2013-04-29	2019-05-08	Mapi Pharma Limited	Dapagliflozin lactose co-crystal
CN104829572B (zh)	2014-02-10	2019-01-04	江苏豪森药业集团有限公司	达格列净新晶型及其制备方法
JP6575470B2 (ja)	2016-09-07	2019-09-18	トヨタ自動車株式会社	走行装置

2008
- 2008-03-19 PE PE2008000514A patent/PE20090185A1/es not_active Application Discontinuation
- 2008-03-19 TW TW097109650A patent/TW200904405A/zh unknown
- 2008-03-19 AR ARP080101176A patent/AR065809A1/es unknown
- 2008-03-20 CL CL2008000823A patent/CL2008000823A1/es unknown
- 2008-03-21 KR KR1020097021954A patent/KR101454051B1/ko not_active Ceased
- 2008-03-21 MX MX2017015125A patent/MX374797B/es unknown
- 2008-03-21 MX MX2011010219A patent/MX352480B/es unknown
- 2008-03-21 KR KR1020147013278A patent/KR101502292B1/ko active Active
- 2008-03-21 DK DK08732695.5T patent/DK2139494T3/da active
- 2008-03-21 CN CN201210201489.XA patent/CN102743340B/zh active Active
- 2008-03-21 HU HUE12153939A patent/HUE062284T2/hu unknown
- 2008-03-21 BR BRPI0809233-8A patent/BRPI0809233B1/pt active IP Right Grant
- 2008-03-21 PT PT87326955T patent/PT2139494T/pt unknown
- 2008-03-21 CN CN2008800169027A patent/CN101686988B/zh active Active
- 2008-03-21 LT LTEP08732695.5T patent/LT2139494T/lt unknown
- 2008-03-21 ES ES12153939T patent/ES2950089T3/es active Active
- 2008-03-21 EA EA200901277A patent/EA020288B1/ru not_active IP Right Cessation
- 2008-03-21 KR KR1020167002023A patent/KR20160013276A/ko not_active Ceased
- 2008-03-21 EA EA201490477A patent/EA027769B1/ru not_active IP Right Cessation
- 2008-03-21 ES ES08732695T patent/ES2791682T3/es active Active
- 2008-03-21 MX MX2009010155A patent/MX2009010155A/es active IP Right Grant
- 2008-03-21 LT LTEP12153939.9T patent/LT2508188T/lt unknown
- 2008-03-21 BR BR122017015098A patent/BR122017015098B8/pt active IP Right Grant
- 2008-03-21 JP JP2010501128A patent/JP5475636B2/ja active Active
- 2008-03-21 SI SI200832124T patent/SI2139494T1/sl unknown
- 2008-03-21 EP EP08732695.5A patent/EP2139494B1/en active Active
- 2008-03-21 FI FIEP12153939.9T patent/FI2508188T3/fi active
- 2008-03-21 HR HRP20230691TT patent/HRP20230691T1/hr unknown
- 2008-03-21 DK DK12153939.9T patent/DK2508188T3/da active
- 2008-03-21 AU AU2008228714A patent/AU2008228714B2/en active Active
- 2008-03-21 KR KR1020147028247A patent/KR101532188B1/ko active Active
- 2008-03-21 PL PL12153939.9T patent/PL2508188T3/pl unknown
- 2008-03-21 MX MX2020009329A patent/MX2020009329A/es unknown
- 2008-03-21 CA CA2929811A patent/CA2929811C/en active Active
- 2008-03-21 EP EP12153939.9A patent/EP2508188B1/en active Active
- 2008-03-21 CA CA2681526A patent/CA2681526C/en active Active
- 2008-03-21 EP EP23170640.9A patent/EP4245299A3/en active Pending
- 2008-03-21 PL PL08732695T patent/PL2139494T3/pl unknown
- 2008-03-21 SI SI200832211T patent/SI2508188T1/sl unknown
- 2008-03-21 US US12/053,442 patent/US7851502B2/en active Active
- 2008-03-21 PT PT121539399T patent/PT2508188T/pt unknown
- 2008-03-21 WO PCT/US2008/057888 patent/WO2008116179A1/en active Application Filing
- 2008-03-21 HU HUE08732695A patent/HUE048897T2/hu unknown
- 2008-03-21 RS RS20200560A patent/RS60258B1/sr unknown
- 2008-03-21 KR KR1020157005482A patent/KR101772776B1/ko active Active
2010
- 2010-11-18 US US12/949,473 patent/US8221786B2/en active Active
2012
- 2012-06-21 US US13/529,463 patent/US8361972B2/en active Active
2013
- 2013-01-04 US US13/734,655 patent/US8716251B2/en active Active
- 2013-03-18 HK HK13103307.7A patent/HK1176004A1/xx unknown
2014
- 2014-02-06 JP JP2014021320A patent/JP5813147B2/ja active Active
- 2014-05-02 US US14/267,984 patent/US9198925B2/en active Active
2020
- 2020-05-11 HR HRP20200753TT patent/HRP20200753T1/hr unknown
- 2020-05-22 CY CY20201100467T patent/CY1123143T1/el unknown
- 2020-07-10 LT LTPA2020522C patent/LTPA2020522I1/lt unknown
- 2020-07-15 CY CY2020022C patent/CY2020022I2/el unknown
- 2020-08-12 NO NO2020028C patent/NO2020028I1/no unknown
- 2020-08-31 FR FR20C1042C patent/FR20C1042I1/fr active Active
- 2020-09-09 HU HUS2000036C patent/HUS2000036I1/hu unknown
2023
- 2023-07-27 CY CY20231100370T patent/CY1126112T1/el unknown

Also Published As

Publication number	Publication date
HUE062284T2 (hu)	2023-10-28
EP2508188A1 (en)	2012-10-10
EP4245299A3 (en)	2023-12-13
ES2950089T3 (es)	2023-10-05
EP2139494A1 (en)	2010-01-06
EA200901277A1 (ru)	2010-02-26
US9198925B2 (en)	2015-12-01
BR122017015098B1 (pt)	2018-05-15
US8221786B2 (en)	2012-07-17
TW200904405A (en)	2009-02-01
FI2508188T3 (fi)	2023-07-19
CL2008000823A1 (es)	2008-11-14
LT2508188T (lt)	2023-07-25
CN102743340B (zh)	2015-07-15
AU2008228714B2 (en)	2013-12-19
CN102743340A (zh)	2012-10-24
HUS2000036I1 (hu)	2020-10-28
JP5475636B2 (ja)	2014-04-16
US20120263786A1 (en)	2012-10-18
JP2010522244A (ja)	2010-07-01
HRP20230691T1 (hr)	2023-10-13
MX2009010155A (es)	2009-10-12
AU2008228714A1 (en)	2008-09-25
CY1126112T1 (el)	2023-11-15
AR065809A1 (es)	2009-07-01
PE20090185A1 (es)	2009-02-28
BR122017015098B8 (pt)	2021-07-27
KR20140069365A (ko)	2014-06-09
HK1176004A1 (en)	2013-07-19
CY1123143T1 (el)	2020-11-25
EA027769B1 (ru)	2017-08-31
US20080234366A1 (en)	2008-09-25
EP4245299A2 (en)	2023-09-20
KR101772776B1 (ko)	2017-08-29
CA2929811C (en)	2019-04-16
US20140243262A1 (en)	2014-08-28
EP2139494B1 (en)	2020-03-11
LT2139494T (lt)	2020-05-25
LTPA2020522I1 (lt)	2020-07-27
NO2020028I1 (no)	2020-08-12
MX374797B (es)	2025-03-06
BRPI0809233A2 (pt)	2014-09-02
KR101454051B1 (ko)	2014-10-27
CN101686988B (zh)	2013-12-11
KR20140124874A (ko)	2014-10-27
US8716251B2 (en)	2014-05-06
CY2020022I1 (el)	2020-11-25
EA201490477A1 (ru)	2014-06-30
US20130129819A1 (en)	2013-05-23
BRPI0809233B1 (pt)	2017-09-26
FR20C1042I1 (fr)	2020-10-16
HUE048897T2 (hu)	2020-08-28
CY2020022I2 (el)	2020-11-25
CN101686988A (zh)	2010-03-31
HRP20200753T1 (hr)	2020-07-24
DK2139494T3 (da)	2020-05-25
EA020288B1 (ru)	2014-10-30
KR20150038555A (ko)	2015-04-08
MX352480B (es)	2017-11-27
KR101502292B1 (ko)	2015-03-12
MX2020009329A (es)	2022-04-26
CA2929811A1 (en)	2008-09-25
PL2139494T3 (pl)	2020-09-21
SI2139494T1 (sl)	2020-07-31
RS60258B1 (sr)	2020-06-30
CA2681526A1 (en)	2008-09-25
WO2008116179A1 (en)	2008-09-25
ES2791682T3 (es)	2020-11-05
PT2508188T (pt)	2023-07-24
KR20160013276A (ko)	2016-02-03
US7851502B2 (en)	2010-12-14
DK2508188T3 (da)	2023-07-31
EP2508188B1 (en)	2023-05-10
JP5813147B2 (ja)	2015-11-17
US8361972B2 (en)	2013-01-29
CA2681526C (en)	2016-07-19
SI2508188T1 (sl)	2023-09-29
JP2014111636A (ja)	2014-06-19
KR20090123964A (ko)	2009-12-02
KR101532188B1 (ko)	2015-06-29
US20110064801A1 (en)	2011-03-17
PL2508188T3 (pl)	2023-09-11

Publication	Publication Date	Title
HK1176004A1 (en)	2013-07-19	Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
ZA201302877B (en)	2015-01-28	Propylene glycol/glycerin-based deodorant
HK1152478A1 (en)	2012-03-02	Solid pharmaceutical formulations comprising bibw 2992
GB0703507D0 (en)	2007-04-04	Solid pharmaceutical dose
IL199863A0 (en)	2010-04-15	Protein formulations containing sorbitol
IL187748A0 (en)	2008-04-13	Pharmaceutical compositions containing misoprostal
HK1146895A1 (en)	2011-07-22	Pharmaceutical preparations containing highly volatile silicones
RS58950B1 (sr)	2019-08-30	Farmaceutske kompozicije koje sadrže korteksolon-17-alfa-propionat
IL198160A0 (en)	2009-12-24	Pharmaceutical formulations
HU0700755D0 (en)	2008-01-28	Pharmaceutical compositions containing capsaicionid
GB0615461D0 (en)	2006-09-13	Pharmaceutical formulations
GB0810217D0 (en)	2008-07-09	Pharmaceutical formulations
GB0813031D0 (en)	2008-08-20	Pharmaceutical formulations